Chek the Channels
Meet 125 Mgmt Teams
Onconova Therapeutics Inc. (ONTX)
Completion of Enrollment is Pushed Back but Data Readout is on Track
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Ahu Demir, Ph.D, Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- INSPIRE remains the main focus of the company. Onconova yesterday announced that patient enrollment in the INSPIRE study reached 324 patients representing 90% of the target (324/360 patients). The completion of enrollment is now anticipated in Q1 2020 instead of Q4 2019. However, topline data readout from this study remains on target and it is anticipated in H1 2020.
- Follows Recent Additional Awards. The company is assessing rigosertib, a RAS pathway inhibitor, in Phase 3 INSPIRE study for the treatment of 2nd line high-risk myelodysplastic syndrome (HR-MDS). ...
This Company Sponored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.